Premium
Studies on an Iron‐poly (sorbitol‐gluconic acid) complex for Parenteral Use in Man
Author(s) -
Andersson Nils S. E.,
Grafford Kerstin
Publication year - 1977
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1977.tb01246.x
Subject(s) - sorbitol , chemistry , gluconic acid , iron deficiency , medicine , zoology , endocrinology , biochemistry , anemia , biology
A comparative study of a new iron carbohydrate complex, iron‐poly (sorbitol‐gluconic acid) complex (Ferastral®) and iron‐sorbitol (Jectofer®) has been performed. In all, 31 patients with iron deficiency anaemia have been treated, 23 with Ferastral and 8 with iron‐sorbitol. The total doses of Ferastral have been 1 000 mg to 2 000 mg of iron given at weekly intervals in single doses of 500 mg. Iron‐sorbitol was given daily in a dose of 100 mg of iron up to a total dose of 1 300 mg. After single doses of 500 mg of Ferastral, levels of iron and unsaturated iron binding capacity (UIBC) in serum were estimated. The iron concentration in serum reached a maximum level 24 to 48 hours after the injection. After that a continuous decrease was observed, but after seven days still higher levels than before treatment were seen. A decrease in the UIBC was observed, and 24 to 48 hours after the injection about half of the initial capacity still remained. After further 3 to 4 days the initial value of UIBC was obtained. The renal excretion of iron varied between 7% and 25% in the patients treated with Ferastral in single doses of 500 mg of iron. The haemoglobin response was of the same magnitude for Ferastral and iron sorbitol. After two weeks the mean increase was 1.6 g/100 ml for both preparations and after four weeks 3.1 g/100 ml for Ferastral and 2.6 g/100 ml for iron‐sorbitol. No effects on liver and kidney functions during treatment with Ferastral, and no changes were observed in serum electrolytes or ECG. No general side effects were observed in the patients treated with Ferastral. In five patients discolouration at the site of injection was observed. One patient experienced an intensive pain in one buttock, which persisted for 12 hours. No pain was felt in the other buttock in which iron was injected at the same time. In the patients treated with iron‐sorbitol, local discomfort was relatively common.